J. Anim Sci.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, D. J.

Journal of Animal Science, Vol 76, Issue 1 173-194, Copyright © 1998 by American Society of Animal Science

JOURNAL ARTICLE

The pharmacokinetics, metabolism, and tissue residues of beta-adrenergic agonists in livestock

D. J. Smith
USDA, ARS Biosciences Research Laboratory, Fargo, ND 58105, USA.

Since the early 1980s the usefulness of dietary beta-agonists to improve the efficiency of feed utilization and(or) to enhance carcass leanness in livestock species has been well documented. Less well documented are the pharmacokinetic properties, biotransformation pathways, and tissue residue profiles of beta-agonists used to enhance leanness in experimentally or illegally treated animals. Pharmacokinetic data for clenbuterol, cimaterol, fenoterol, L-644,969, ractopamine, salbutamol, and terbutaline have been published but biotransformation and tissue residue studies for these compounds in livestock species are sparse. In general, beta-agonists having halogenated aromatic ring systems are metabolized by oxidative and conjugative pathways and have long plasma half-lives, whereas beta-agonists having hydroxylated aromatic rings are metabolized solely by conjugation and have relatively short plasma half-lives. Beta-Agonists having high oral bioavailabilities, long plasma half-lives, and relatively slow rates of elimination have high oral potencies in humans. Residues of such illegally used compounds in edible tissues of livestock represent a genuine risk to consumers. Conversely, beta-agonists having low oral bioavailabilities, short plasma half-lives, and rapid rates of elimination have low oral potencies in humans. Residues of such compounds in edible tissues of properly treated animals would not likely represent a credible risk to consumers of such products. The reviewed data indicate that the development of a safe and effective beta-agonist for use in livestock is possible.


This article has been cited by other articles:


Home page
 J ANIM SCIHome page
S. E. Mills, M. E. Spurlock, and D. J. Smith
{beta}-Adrenergic receptor subtypes that mediate ractopaminestimulation of lipolysis
J Anim Sci, March 1, 2003; 81(3): 662 - 668.
[Abstract] [Full Text] [PDF]

Home page
 J ANIM SCIHome page
S. E. Mills, J. Kissel, C. A. Bidwell, and D. J. Smith
Stereoselectivity of porcine {beta}-adrenergic receptors for ractopamine stereoisomers
J Anim Sci, January 1, 2003; 81(1): 122 - 129.
[Abstract] [Full Text] [PDF]

Home page
 J ANIM SCIHome page
D. J. Smith, K. M. Ehrenfried, J. D. Dalidowicz, and M. P. Turberg
Binding of ractopamine HCl to ocular tissues of cattle and turkeys in vivo and to melanin in vitro
J Anim Sci, November 1, 2002; 80(11): 2931 - 2941.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Society of Animal Science.